A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT05283720. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximately 496 adult participants with NHL will be enrolled in 100 sites globally. In both the dose escalation and dose expansion arms participants will receive subcutaneous (SC) epcoritamab in 28 day, 21 day, or 56 day cycles dependent on the arm in combination with the anti-neoplastic agents described below: 1: Oral lenalidomide in participants (PPTS) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); 2: Oral ibrutinib and oral lenalidomide in PPTS with R/R DLBCL; 3: Intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in PPTS with newly diagnosed treatment-naïve DLBCL, or completion of treatment in 3B; 4: Oral CC-99282 in PPTS with R/R DLBCL; 5: Oral CC-99282 in PPTS with R/R follicular lymphoma (FL); 6A: Oral ibrutinib in PPTS with R/R mantle cell lymphoma (MCL). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Study identification
- NCT ID
- NCT05283720
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 264 participants
Conditions and interventions
Conditions
Interventions
- Epcoritamab Drug
- Lenalidomide Drug
- Ibrutinib Drug
- Rituximab Drug
- Cyclophosphamide Drug
- Doxorubicin Hydrochloride [HCl] Drug
- Prednisone Drug
- Polatuzumab Vedotin Drug
- CC-99282 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2022
- Primary completion
- Oct 31, 2032
- Completion
- Oct 31, 2032
- Last update posted
- Jul 6, 2026
2022 – 2032
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center - North Campus /ID# 242219 | Tucson | Arizona | 85719 | — |
| Yale University School of Medicine /ID# 242089 | New Haven | Connecticut | 06510 | — |
| Christiana Care Health Service /ID# 242301 | Newark | Delaware | 19713 | — |
| Tampa General Hospital /ID# 246748 | Tampa | Florida | 33606 | — |
| Winship Cancer Institute of Emory University /ID# 242153 | Atlanta | Georgia | 30322 | — |
| University of Maryland, Baltimore /ID# 242218 | Baltimore | Maryland | 21201 | — |
| Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144 | Kansas City | Missouri | 64114-4859 | — |
| Northwell Health - Monter Cancer Center /ID# 245435 | Lake Success | New York | 11042 | — |
| Icahn School of Medicine at Mount Sinai /ID# 242123 | New York | New York | 10029 | — |
| Novant Health Presbyterian Medical Center /ID# 242148 | Charlotte | North Carolina | 28204 | — |
| East Carolina University - Brody School of Medicine /ID# 242506 | Greenville | North Carolina | 27834 | — |
| Novant Health Forsyth Medical Center /ID# 242198 | Winston-Salem | North Carolina | 27103 | — |
| Thomas Jefferson University Hospital /ID# 242077 | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center /ID# 242106 | Philadelphia | Pennsylvania | 19111 | — |
| Thompson Cancer Survival Ctr /ID# 242150 | Knoxville | Tennessee | 37916 | — |
| Joe Arrington Cancer Research /ID# 242226 | Lubbock | Texas | 79410 | — |
| Swedish Medical Center - Seattle /ID# 242269 | Seattle | Washington | 98104 | — |
| MultiCare Institute for Research and Innovation /ID# 242127 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05283720, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 6, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05283720 live on ClinicalTrials.gov.